SEI Investments’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

SEI Investments’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,814	Closed	-$67K	–	3884
2018 Q1	$67K	Buy	+3,814	New	+$69.8K	﹤0.01%	2265
2015 Q4	–	Sell	-1,600	Closed	-$27K	–	2757
2015 Q3	$27K	Buy	+1,600	New	+$39.8K	﹤0.01%	2015

Other funds holding CBMG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

SEI Investments's CBMG Position: Q2 2018 in Review

SEI Investments sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q2 2018, closing a stake of 3,814 shares — an estimated $67K sold.

SEI Investments first reported a position in CBMG in Q3 2015 and held it in 2 quarters. The position peaked at $67K in Q1 2018. 34 funds tracked by Wall St. Rank hold CBMG as of Q2 2018.

SEI Investments reported no remaining Cellular Biomedicine Group, Inc. position as of Q2 2018 after selling out during the quarter.
SEI Investments sold 3,814 Cellular Biomedicine Group, Inc. shares in Q2 2018, an estimated $67K.
SEI Investments first reported a position in Cellular Biomedicine Group, Inc. in Q3 2015 and held it in 2 quarters.
SEI Investments's Cellular Biomedicine Group, Inc. position peaked at $67K in Q1 2018.
34 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q2 2018.

Based on SEI Investments's 13F filing for Q2 2018, filed 3 Aug 2018.